Identification of Risk of Cardiovascular Disease by Automatic Quantification of Coronary Artery Calcifications on Radiotherapy Planning CT Scans in Patients With Breast Cancer.
Journal
JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
pubmed:
7
5
2021
medline:
12
3
2022
entrez:
6
5
2021
Statut:
ppublish
Résumé
Cardiovascular disease (CVD) is common in patients treated for breast cancer, especially in patients treated with systemic treatment and radiotherapy and in those with preexisting CVD risk factors. Coronary artery calcium (CAC), a strong independent CVD risk factor, can be automatically quantified on radiotherapy planning computed tomography (CT) scans and may help identify patients at increased CVD risk. To evaluate the association of CAC with CVD and coronary artery disease (CAD) in patients with breast cancer. In this multicenter cohort study of 15 915 patients with breast cancer receiving radiotherapy between 2005 and 2016 who were followed until December 31, 2018, age, calendar year, and treatment-adjusted Cox proportional hazard models were used to evaluate the association of CAC with CVD and CAD. Overall CAC scores were automatically extracted from planning CT scans using a deep learning algorithm. Patients were classified into Agatston risk categories (0, 1-10, 11-100, 101-399, >400 units). Occurrence of fatal and nonfatal CVD and CAD were obtained from national registries. Of the 15 915 participants included in this study, the mean (SD) age at CT scan was 59.0 (11.2; range, 22-95) years, and 15 879 (99.8%) were women. Seventy percent (n = 11 179) had no CAC. Coronary artery calcium scores of 1 to 10, 11 to 100, 101 to 400, and greater than 400 were present in 10.0% (n = 1584), 11.5% (n = 1825), 5.2% (n = 830), and 3.1% (n = 497) respectively. After a median follow-up of 51.2 months, CVD risks increased from 5.2% in patients with no CAC to 28.2% in patients with CAC scores higher than 400. After adjustment, CVD risk increased with higher CAC score (hazard ratio [HR]CAC = 1-10 = 1.1; 95% CI, 0.9-1.4; HRCAC = 11-100 = 1.8; 95% CI, 1.5-2.1; HRCAC = 101-400 = 2.1; 95% CI, 1.7-2.6; and HRCAC>400 = 3.4; 95% CI, 2.8-4.2). Coronary artery calcium was particularly strongly associated with CAD (HRCAC>400 = 7.8; 95% CI, 5.5-11.2). The association between CAC and CVD was strongest in patients treated with anthracyclines (HRCAC>400 = 5.8; 95% CI, 3.0-11.4) and patients who received a radiation boost (HRCAC>400 = 6.1; 95% CI, 3.8-9.7). This cohort study found that coronary artery calcium on breast cancer radiotherapy planning CT scan results was associated with CVD, especially CAD. Automated CAC scoring on radiotherapy planning CT scans may be used as a fast and low-cost tool to identify patients with breast cancer at increased risk of CVD, allowing implementing CVD risk-mitigating strategies with the aim to reduce the risk of CVD burden after breast cancer. ClinicalTrials.gov Identifier: NCT03206333.
Identifiants
pubmed: 33956083
pii: 2779524
doi: 10.1001/jamaoncol.2021.1144
pmc: PMC8283560
doi:
Banques de données
ClinicalTrials.gov
['NCT03206333']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1024-1032Références
J Clin Oncol. 2018 Sep 10;36(26):2710-2717
pubmed: 29584550
Maturitas. 2017 Nov;105:37-45
pubmed: 28583397
J Am Heart Assoc. 2017 May 21;6(5):
pubmed: 28529208
Radiother Oncol. 2018 Jan;126(1):170-176
pubmed: 29089148
Br J Cancer. 2018 Aug;119(4):408-418
pubmed: 30065254
J Am Coll Cardiol. 2018 Jul 24;72(4):434-447
pubmed: 30025580
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
JAMA. 2016 Nov 22;316(20):2126-2134
pubmed: 27846641
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
Radiother Oncol. 2018 Jun;127(3):487-492
pubmed: 29703498
Mol Clin Oncol. 2019 Jul;11(1):15-23
pubmed: 31289672
BMC Cancer. 2010 Jun 29;10:337
pubmed: 20587042
IEEE Trans Med Imaging. 2018 Feb;37(2):615-625
pubmed: 29408789
Radiother Oncol. 2020 Aug;149:78-83
pubmed: 32407743
J Natl Cancer Inst. 2007 Mar 7;99(5):365-75
pubmed: 17341728
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Radiology. 2020 Apr;295(1):66-79
pubmed: 32043947
Eur Heart J. 2019 Dec 21;40(48):3889-3897
pubmed: 31761945
Radiother Oncol. 2019 Feb;131:202-207
pubmed: 30097250
J Clin Oncol. 2018 Aug 1;36(22):2288-2296
pubmed: 29791285
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
BMJ Open. 2019 Jul 27;9(7):e028752
pubmed: 31352417
PLoS One. 2016 Dec 9;11(12):e0167925
pubmed: 27936125
Epidemiology. 2016 Jan;27(1):6-13
pubmed: 26414938